TaiMed Biologics Inc. (TPEX:4147)

Market Cap	16.69B -13.7%
Revenue (ttm)	619.49M +3.6%
Net Income	-138.90M
EPS	-0.51
Shares Out	273.20M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	592,405
Open	60.00
Previous Close	59.50
Day's Range	60.00 - 61.90
52-Week Range	47.00 - 76.80
Beta	-0.07
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About TaiMed Biologics

TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases. The company develops and markets Trogarzo IV infusion and Trogarzo IV push, a monoclonal antibody for HIV treatment. It is also developing TMB-365, a monoclonal antibody used for HIV treatment and prevention which has completed a phase-1 clinical trial; and TMB-365 and TMB-380 combination, a monoclonal antibody combination therapy for HIV that is in phase-1b/2a clinical trial, as well as antib...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4147

Financial Performance

In 2025, TaiMed Biologics's revenue was 611.35 million, an increase of 0.19% compared to the previous year's 610.16 million. Losses were -167.78 million, -16.87% less than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 16, 2026

Data Sources Report a data error